Ligand Pharmaceuticals (LGND) Cash & Current Investments (2010 - 2026)

Ligand Pharmaceuticals' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $779.4 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 273.1% year-over-year to $779.4 million; the TTM figure through Mar 2026 stood at $779.4 million (up 273.1% YoY), while the FY2025 annual figure was $190.6 million, down 25.61% from the prior year.
• Cash & Current Investments came in at $779.4 million for Q1 2026 at Ligand Pharmaceuticals, up from $190.6 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $779.4 million in Q1 2026 to a low of $74.8 million in Q3 2024.
• A 5-year average of $265.0 million and a median of $211.9 million in 2022 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments plunged 62.44% in 2022 and jumped 788.97% in 2025, its largest moves.
• Ligand Pharmaceuticals' Cash & Current Investments stood at $211.9 million in 2022, then retreated by 19.62% to $170.3 million in 2023, then soared by 50.41% to $256.2 million in 2024, then declined by 25.61% to $190.6 million in 2025, then jumped by 309.01% to $779.4 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $779.4 million, $190.6 million, and $664.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison